Search clinical trials for: ATG-010

Total 1632 results

Antengene Corporation

Terminated

A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (MATCH)

Relapsed/Refractory Diffuse Large B-cell Lymphoma

China
Xia Zhongjun
Antengene Corporation

Recruiting

Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma

Multiple Myeloma

China
Qi Zhou

Not yet recruiting

A Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( PORCH ) (PORCH)

1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical Cancer

China
Li Zheng

Not yet recruiting

Selinexor in Combination With Thalidomide and Dexamethasone in RRMM

Multiple Myeloma

China
Chunyan Sun, MD

Recruiting

ATG-010(Selinexor) in Combination With Chemotherapy in RRMM

Multiple Myeloma

China
Antengene Corporation

Active, not recruiting

A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (SEARCH)

Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

China
Juan Du

Recruiting

Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM

Multiple Myeloma

China
Antengene Corporation

Completed

A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma (MARCH)

Relapse/Refractory Multiple Myeloma

China
Li Zhiming
Antengene Corporation

Recruiting

Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

DLBCL Germinal Center B-Cell Type

China
Mamta Parikh
National Cancer Institute (NCI); Karyopharm Therapeutics Inc

Recruiting

Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Metastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Refractory Urothelial Carcinoma

United States
Antengene Corporation

Recruiting

A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma (TOUCH)

Peripheral T-cell Lymphoma | NK/T-cell Lymphoma

China
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

Malignant Glioma | WHO Grade 3 Glioma | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Refractory Primary Central Nervous System Neoplasm | Recurrent Childhood Central Nervous System Neoplasm | Recurrent Brain Neoplasm | Recurrent Childhood...

United States
Tong Chen
Antengene Corporation

Recruiting

Selinexor in Combination With MTX+Ritu to Treat R/R CNSL

Central Nervous System Lymphoma

China
Peking University People's Hospital

Completed

Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis

Leukemia, GVHD, ATG, Transplantation

China
National Cancer Institute (NCI)

Recruiting

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory Plasma Cell Myeloma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Non-Hodgkin Lymphoma | Refractory Histiocytic and Dendritic Cell Neoplasm | Refractory Non-Hodgkin Lymphoma | Recurrent Plasma Cell Myeloma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Metastatic Renal Cell Carcinoma | Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Metastatic Melanoma | Fallopian Tube Carcinoma | Advanced Malignant Solid Neoplasm | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage III Renal... and other conditions

United States
Assaf-Harofeh Medical Center

Unknown

Reducing Urethral Pain During Urodynamic Test - Comparison Between Lidocaine Gel and Paraffin Oil

Pain

Israel
National Cancer Institute (NCI)

Recruiting

Testing Atezolizumab With or Without Selinexor in Patients >= 18 Years Old With Alveolar Soft Part Sarcoma, the Axiom Study

Metastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part Sarcoma

United States
Antengene Corporation

Recruiting

A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL (SWATCH)

Diffuse Large B-cell Lymphoma | Indolent Non-Hodgkin Lymphoma

China
National Cancer Institute (NCI)

Suspended

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Glioblastoma | Malignant Glioma | Anaplastic Astrocytoma | Anaplastic Astrocytoma, Not Otherwise Specified | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | Glioblastoma, Not Otherwise Specified

United States, Canada, Australia, New Zealand
National Cancer Institute (NCI)

Suspended

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Recurrent Glioblastoma, IDH-Wildtype | MGMT-Methylated Glioblastoma | Recurrent MGMT-Methylated Glioblastoma

United States
Contera Pharma
Bukwang Pharmaceutical

Active, not recruiting

A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia (ASTORIA)

Dyskinesias

France, Germany, Italy, Korea, Republic of, Spain
Antengene Corporation

Active, not recruiting

A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) (BENCH)

Relapsed or Refractory Multiple Myeloma

China
Kafrelsheikh University

Completed

Ridge Augmentation With Simultaneous Implant Placement Using Bone Blocks With Autogenous Tooth Graft

Implant | Ridge Augmentation | Autogenous Tooth Graft

Egypt
Synthetic Biologics Inc.

Completed

A Study of the Effect of SYN-010 on Subjects With IBS-C

Irritable Bowel Syndrome With Constipation (IBS-C)

United States
Tianjin First Central Hospital

Unknown

Observational Study to Evaluate the Safety and Efficacy of Polyclonal Antibodies in Simultaneous Pancreas Kidney Transplant Recipients (PAISPK)

Diabetes Mellitus | CKD (Chronic Kidney Disease) Stage 5T | Simultaneous Pancreas Kidney Transplantation

China
IRCCS Burlo Garofolo

Completed

Lymphocyte Count, ATG Dose and Incidence and Severity of GVHD in Pediatric Recipients of HSCT

Hematopoietic Stem Cell Transplantation

Italy
Bukwang Pharmaceutical

Active, not recruiting

Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components (SHINE)

Parkinson Disease | Dyskinesias

United States
McMaster University
Sanofi; Ozmosis Research Inc.; Cell Therapy Transplant Canada

Recruiting

ATG Plus PTCy vs ATG for CGVHD Prophylaxis

Acute Leukemia | Myelodysplasia | Chronic Graft-versus-host-disease

Canada, Australia
University Hospital, Toulouse
Novartis; Neovii Biotech

Completed

Simulect Versus ATG in Sensitized Renal Transplant Patient (SATIR)

Renal Transplant Rejection

France
Fujian Medical University

Unknown

ATG-F VS ATG for the Prevention of GVHD

GVHD in the Setting of Haplo-HSCT

China
Chinese PLA General Hospital

Recruiting

Individualized Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation

Haploidentical Hematopoietic Stem Cell Transplantation

China
Biocad

Recruiting

A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A (EDELWEISS)

Hemophilia A

Russian Federation
Memorial Sloan Kettering Cancer Center

Completed

Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer

Breast Cancer | Invasive Adenocarcinoma of the Breast

United States
National Institute of Diabetes and Digestive and...
National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaborators

Completed

ATG-GCSF in New Onset Type 1 Diabetes (ATG-GCSF)

Diabetes Mellitus, Type 1

United States
Guangzhou Gloria Biosciences Co., Ltd.

Not yet recruiting

GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)

Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma | Classic Hodgkin's Lymphoma
Antengene (Hangzhou) Biologics Co., Ltd.

Recruiting

A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

Advanced Solid Tumor | Metastatic Solid Tumor | Mature B-cell Non-Hodgkin Lymphoma

China
Tianjin Chasesun Pharmaceutical Co., LTD

Enrolling by invitation

A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors

Malignant Neoplasms

China
Synthetic Biologics Inc.

Completed

A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With IBS-C

Irritable Bowel Syndrome With Constipation (IBS-C)

United States
Astellas Pharma China, Inc.

Completed

Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant Recipients

Kidney Transplant Recipients

China
Shanghai General Hospital, Shanghai Jiao Tong University...

Unknown

Low Dose ATG Plus Low Dose PTCy as GVHD Prophylaxis in Haplo-HSCT (ATG/PTCy)

Prophylaxis | Graft-versus-host-disease

China
medac GmbH

Completed

Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML)

Acute Myeloid Leukaemia

Germany
BioMimetix JV, LLC

Terminated

Evaluation of Topical Application of BMX-010 in Subjects With Acne Vulgaris.

Acne Vulgaris

United States
Shanghai General Hospital, Shanghai Jiao Tong University...

Completed

ATG/PTCy in Haplo-PBSCT Randomized Controlled,Multi-center (ATG/PTCy)

Myeloid Tumor

China
Alexza Pharmaceuticals, Inc.
Celerion

Completed

Staccato® Granisetron Multiple Dose PK

Healthy

United States
Orca Therapeutics B.V.
CMX Research

Active, not recruiting

First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients.

Adenocarcinoma of the Prostate

Canada
BioMimetix JV, LLC

Completed

Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis

Psoriasis | Atopic Dermatitis

United States

Search clinical trials for: ATG-010

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations